Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase I Dose-escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-C4.4a Antibody Drug Conjugate BAY1129980 in Subjects With Advanced Solid Tumors Known to Express C4.4a

NCT02134197 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02134197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02134197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase I Dose-escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-C4.4a Antibody Drug Conjugate BAY1129980 in Subjects With Advanced Solid Tumors Known to Express C4.4a
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Terminated
Start date
May 22, 2014
Completion date
August 30, 2018
Enrollment
69 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms